Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Fierce Pharma
ASCO: Merck, Kelun's sac-TMT combo beats Keytruda by 65% on PFS
Combining the TROP2 ADC with Keytruda cut the risk of progression or death by 65% versus Keytruda alone in first-line, PD-L1-positive NSCLC.
Angus Liu
May 21, 2026 5:00pm
Regeneron pens $2.3B Parabilis pact to develop new twist on ADCs
May 18, 2026 9:08am
Fierce Pharma
Daiichi Sankyo targets global top 5 oncology rank by 2035
May 11, 2026 10:22am
GSK walks away from $100M bet on Mersana STING ADC
Apr 29, 2026 6:16am
Pfizer cans work on next-gen conjugate in cancer patients
Apr 23, 2026 11:20am
With global goals, Zai Lab offers China reality check
Apr 20, 2026 2:12pm
